HR Execs on the Move

Cerebral

www.cerebral.com

 
At Cerebral, we`re on a mission to democratize access to high-quality mental health care. We believe that everyone everywhere deserves to get the care they need, and are striving to make care convenient and accessible, while tackling the stigmas that surround mental illness. Since launching in January 2020, we have gone from a team of 5 to over 4,000 across the United States. With support from investors like SoftBank, Silver Lake, Access Industries, Bill Ackman, WestCap, and others, and impactful leaders like you, we`ll continue to democratize mental health care and double down on clinical quality and deliver exceptional patient ...
  • Number of Employees: 5K-10K
  • Annual Revenue: $500M-1 Billion
  • www.cerebral.com
  • 2093 Philadelphia Pike #9898
    Claymont, DE USA 19703
  • Phone: 415.403.2156

Executives

Name Title Contact Details
Katie Bergin
Director, People & Talent Profile
Brittney Henderson
Head of Marketing Profile
Kevin Callender
Chief People Officer Profile

Similar Companies

HealthEconomics.Com

HealthEconomics.Com is the worlds most comprehensive and credible website for resources and jobs in healthcare value and market access.

Artios Pharma

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.

Honor Community Health

Honor Community Health (OIHN) is an HRSA-qualified community health center providing primary, behavioral health and dental care throughout Oakland County, Michigan.

New Health Sciences

New Health Sciences is developing Hemanext, a technology designed to improve the safety and efficacy of transfusion therapy through novel storage methods.

Tricol Biomedical

Tricol Biomedical is dedicated to significantly advancing the standard of care in hemostatic and wound care management with a broad array of products.